Postoperative Analgesic Effects of Dexmedetomidine for Transversus Abdominis Plane Block

Postoperative Analgesic Effects of Dexmedetomidine Added to Bupivacaine for Transversus Abdominis Plane Block for Lower Abdominal Surgery

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02064530

Acronym

TAP

Enrollment

Registered

2014-02-17

Start date

2014-02-28

Completion date

2015-09-30

Last updated

2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

TAP block, dexmedetomidine, bupivacaine, postoperative analgesia

Brief summary

the aim of this study is evaluate postoperative analgesic effects of dexmedetomidine added to bupivacaine on TAP block in patients undergoing lower abdominal surgery.

Detailed description

TAP block is being used a method of multimodal balanced analgesia reduces postoperative pain, opioid requirement after surgery and adverse effect of opioid such as sedation, nausea vomiting and ileus. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist, is being used and adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.

Interventions

DRUGBupivacaine

21 ml 0.5 %bupivacaine is applied interfasially

DRUGDexmedetomidine

1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially

DRUGserum physiologic

21 ml serum physiologic is applied interfasially

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ASA 1-2 * 18-65 aged * patient undergoing lower abdominal surgery

Exclusion criteria

* chronic opioid consumption * bupivacaine and dexmedetomidine allergies * coagulopathy * infection at the needle insertion side * chronic liver and kidney disease

Design outcomes

Primary

Measure	Time frame	Description
opioid consumption	postoperative 1 day	patient controlled analgesia

Secondary

Measure	Time frame
visual analog scale	postoperative 1 day

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026